To study the availability of new launched products of Zydus cadila

750 views

Published on

Market Research carried out in two cities of Gujarat- Ahmedabad and Rajkot- which gave an insight about the availability of newly launched products in medical stores. It also contains area wise availablity and leading brands.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
750
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

To study the availability of new launched products of Zydus cadila

  1. 1. MARKET RESEARCH CONDUCTED ONNEW LAUNCHED PRODUCTS OFZYDUS CADILAProject Manager: Mrs. Babita Goyal(Strategic Marketing Cell)Survey conducted, analysed and presented byJay Nirmal
  2. 2. INTRODUCTION Indian pharmaceutical market reached US$ 21.72billion ( as of June 2011). It is growing at the rate of 8-9% annually. Thousands of new products are launched eachyear. Zydus Cadila has come up with many new productsin recent past.
  3. 3. RESEARCH OBJECTIVETo check out the availability of newlaunched products of ZydusCadila
  4. 4. RESEARCH METHODOLOGY Type of Research Design: Descriptive research Sample Design: Probability sampling Stratified Random sampling Sampling Frame: Medical store Sample Size: 175 Data Collection: Primary data is collected through Schedules
  5. 5. MOLECULES BRANDSLacosamide LacasaSodium Valproate Epima ChronoTelmisartan Inditel, Inditel AMMetoprolol Sustamet, Sustamet AMRosuvastatin Zyrova, Zyrova F
  6. 6. Selling Total selling ofLacosamide molecule=2795 Tablets Total selling of Lacasa=0 % selling= 0%Selling Total selling ofLacosamide molecule=Not found Total selling of Lacasa=Not found % selling= --AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  7. 7. Availability No. of medical storeshaving Lacosamidemolecule = 13 No. of medical storeshaving Lacasa brand= 0 % availability= 0%Availability No. of medical storeshaving Lacosamidemolecule = 4 No. of medical storeshaving Lacasa brand= 1 % availability= 25%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  8. 8. Known No. of medical stores nothaving Lacasa= 13 No. of medical store thatdid not knew about thisbrand= 12 % unknown= 92.30%Known No. of medical stores nothaving Lacasa= 3 No. of medical store thatdid not knew about thisbrand= 3 % unknown= 100%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  9. 9.  Highest selling brands  Highest selling brandsAHMEDABAD RAJKOT02468101214Preffered00.511.522.5PrefferedLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  10. 10. Selling Total selling of SodiumValproate molecule=43240 Tablets Total selling of EpimaChrono= 55 % selling= 0.13%Selling Total selling of SodiumValproate molecule=15750 Tablets Total selling of EpimaChrono= 1050 %selling= 6.67%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  11. 11. Availability No. of medical storeshaving Sodium Valproatemolecule = 94 No. of medical storeshaving EpimaChronobrand= 8 % availability= 8.51%Availability No. of medical storeshaving Sodium Valproatemolecule = 68 No. of medical storeshaving EpimaChronobrand= 10 % availability= 14.71%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  12. 12. Known No. of medical stores nothaving Epima Chrono=86 No. of medical store thatdid not knew about thisbrand= 68 % unknown= 79.07%Known No. of medical stores nothaving Epima Chrono=58 No. of medical store thatdid not knew about thisbrand= 42 % unknown= 72.41%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  13. 13. AHMEDABAD RAJKOT Highest selling brands  Highest selling brands0102030405060708090ValparinValprolEnchorateEpilexTorvateValprosinDivaDiproxPreffered0102030405060ValparinEpilexValprolEnchorateValprosinPreferredLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  14. 14. Selling Total selling of Telmisartanmolecule= 33890 tabs Total selling of Inditel= 2900 tabs Total selling of Inditel AM= 2340tabs Combined selling= 5240 tabs % selling= 15.46%Selling Total selling of Telmisartanmolecule= 18000 tabs Total selling of Inditel= 3075 tabs Total selling of Inditel AM= 1790tabs Combined selling= 4865 tabs % selling= 27.03%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  15. 15. Availability No. of medical stores havingTelmisartan molecule = 97 No. of medical stores havingInditel brand= 60 % availability= 70.27% No. of medical stores havingInditel AM brand= 58 % availability= 61.85%Availability No. of medical stores havingTelmisartan molecule = 67 No. of medical stores havingInditel brand= 38 % availability= 72.41% No. of medical stores havingInditel AM brand= 32 % availability= 60%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  16. 16. Known No. of medical stores nothaving Inditel= 37 No. of medical store thatdid not knew about thisbrand= 26 % unknown= 70.27%Known No. of medical storesnot having Inditel= 29 No. of medical storethat did not knew aboutthis brand= 21 % unknown= 72.41%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  17. 17.  CombinationCombination sold(Out of97)-H -AMNo. ofmedicalstores69 57% ofmedicalstores71.13 58.76AHMEDABAD RAJKOTCombinationCombinationsold(Outof 67)-H -AMOthersNo. ofmedicalstores19 8 3% ofmedicalstores28.36 11.94 4.48LACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  18. 18.  Highest selling brandsAHMEDABAD RAJKOT Highest selling brands0102030405060708090TelmaTelsarTelsartanTelpresTelmikindTelvasTazlocTelistaOthersPreff05101520253035TelsarTelmaTelsartanTelmikindTazlocTelvasTelistaTelpresOthersPreffLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  19. 19. Selling Total selling of Metoprololmolecule= 44665 tabs Total selling of Sustamet= 1335tabs Total selling of Sustamet AM=845 tabs Combined selling= 2180 tabs % selling= 4.88%Selling Total selling of Metoprololmolecule= 13525 tabs Total selling of Sustamet= 810tabs Total selling of Sustamet AM= 30tabs Combined selling= 840 tabs % selling= 6.21%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  20. 20. Availability No. of medical stores havingMetoprolol molecule = 92 No. of medical stores havingSustamet brand= 34 % availability= 36.96% No. of medical stores havingSustamet AM brand= 29 % availability= 31.53%Availability No. of medical stores havingMetoprolol molecule = 68 No. of medical stores havingSustamet brand= 12 % availability= % No. of medical stores havingSustamet AM brand= 9 % availability= 66.67%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  21. 21. Known No. of medical stores nothaving Sustamet= 58 No. of medical store thatdid not knew about thisbrand= 44 % unknown= 75.86%Known No. of medical stores nothaving Sustamet= 56 No. of medical store thatdid not knew about thisbrand= 35 % unknown= 62.5%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  22. 22.  Combination sold  Combination soldAHMEDABAD RAJKOTCombinationsold (Out of92)-AMNo. of medicalstores40% of medicalstores43.48Combinationsold (Out of68)-AMNo. of medicalstores3% of medicalstores4.11LACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  23. 23.  Highest selling brands  Highest selling brandsAHMEDABAD RAJKOT05101520253035404550MetolarBetalocMetpureMetocardMetXLSelokenSupermetProlometOthersPreffered0510152025303540MetolarBetalocMetocardMetpureSeokenMetzorProlometMetprinOthersPrefferedLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOL ROSUVASTATIN
  24. 24. Selling Total selling of Rosuvastatinmolecule= 25325 tabs Total selling of Zyrova= 490 tabs Total selling of Zyrova F= 25 tabs Combined selling= 515 tabs % selling= 2.03%Selling Total selling of Rosuvastatinmolecule= 13525 tabs Total selling of Zyrova= 810 tabs Total selling of Zyrova F= 30 tabs Combined selling= 840 tabs % selling= 6.21%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOLROSUVA-STATIN
  25. 25. Availability No. of medical stores havingRosuvastatin molecule = 90 No. of medical stores havingZyrova brand= 15 % availability= 16.67% No. of medical stores havingZyrova F brand= 10 % availability= 11.11%Availability No. of medical stores havingRosuvastatin molecule = 90 No. of medical stores havingZyrova brand= 15 % availability= 29.41% No. of medical stores havingZyrova F brand= 7 % availability= 13.72%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOLROSUVA-STATIN
  26. 26. Known No. of medical stores nothaving Zyrova= 75 No. of medical store thatdid not knew about thisbrand= 59 % unknown= 78.66%Known No. of medical storesnot having Zyrova= 36 No. of medical storethat did not knew aboutthis brand= 32 % unknown= 88.89%AHMEDABAD RAJKOTLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOLROSUVA-STATIN
  27. 27.  Combination sold  Combination soldAHMEDABAD RAJKOTCombinationsold (Out of90)-FNo. of medicalstores30% of medicalstores33.33Combinationsold (Out of51)-FNo. of medicalstores2% of medicalstores3.92LACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOLROSUVA-STATIN
  28. 28.  Highest selling brands  Highest selling brandsAHMEDABAD RAJKOT01020304050607080RosuvasRosucorRozavelCrestorRostarRosetOthersPreffered05101520253035RosuvasRosetRozavelRosucorNovastatRosuv…OthersPrefferedLACOSAMIDESODIUMVALPROATETELMISARTAN METOPROLOLROSUVA-STATIN
  29. 29. FACTOR AFFECTING AVAILABILITY OF DRUGSIN MEDICAL STORES Preference of Doctor Visits of MR Affiliated to Physicians/ Hospitals Central Location
  30. 30. AHMEDABADFor Zydus CadilaPreference of Doctor Doctors don’t prescribe muchStockist availability AvailablePricingAlmost parallel, Not a matter of concern aslong as doctors prescribeSchemesOnly if purchased in bulk, Not a matter ofconcern as long as doctors prescribeSide effect/ Drug interaction Not awareVisits of MRNot regular, in large medical stores andstores affiliated to hospitals
  31. 31. RAJKOTFor Zydus CadilaPreference of Doctor Doctors don’t prescribe muchStockist availability AvailablePricingAlmost parallel, Not a matter of concern aslong as doctors prescribeSchemes Only if purchased in bulkSide effect/ Drug interaction Unaware, Not a factorVisits of MRNot regular, in large stores, no push forsome brands
  32. 32. FEEDBACK FROM MEDICAL STORE OWNERS Better brands available in market Running and set brands already available, no spacefor new products Infrequent or less visits of MR even though aparticular brand sells or is at least kept in themedical store MRs not much interested in selling Push for brands in major medical stores only, inmajor locations Brands still not popular, most medical ownershavent even heard the names Little trust on Zydus Cadila products
  33. 33. SUGGESTIONS FOR AVAILABILITY INAHMEDABADLacasa Reaching out to particular hospitals and MR visits tomedical stores affiliated with these hospitals can helpenhance availabilityEpima Chrono Explaining Doctors for its pharmacological superioritycan helpInditel Utility branding for this molecule Marketing Hydrothiazide combination may enhance thesell.
  34. 34. Sustamet Marketing the molecule to major physicians andsmaller hospitals and then gradually to largerhospitals.Zyrova More MR interaction with the Medical store ownersand regular visit to Doctors can help.
  35. 35. SUGGESTIONS FOR AVAILABILITY IN RAJKOTLacasa Not much market deveolped for Lacosamide, an earlycall for its marketing may help capture the pie.Epima Chrono Explaining Doctors for its pharmacological superioritycan help.Inditel Utility branding for this molecule Marketing Hydrothiazide combination may enhance thesell.
  36. 36. Sustamet More MR interaction with the Medical store ownersand regular visit to Doctors can help.Zyrova More MR interaction with the Medical store ownersand regular visit to Doctors can help.
  37. 37. CONCLUSION As seen from the survey conducted, availability ofdrugs are heavily dependent on prescription ofdoctors, MR follow ups and to what extent thebrands are known by medical store owners. Working on these three factors will help inachieving the objective.
  38. 38. Any Questions???

×